Dynamic Contrast-Enhanced (DCE)-MRI Enhanced With Macromolecular Contrast Media for Monitoring Sorafenib Effect on Experimental Prostate Carcinomas

C. C. Cyran¹, P. M. Paprottka¹, B. Schwarz², S. Sourbron¹, O. Dietrich¹, J. von Einem¹, R. Hinkel¹, C. Bruns², H. Pietsch⁴, M. F. Reiser¹, B. J. Wintersperger¹, and K. Nikolaou¹

¹Institute of Clinical Radiology, Munich University Hospitals - Campus Grosshadern, Munich, Germany, ²Department of Surgery, Munich University Hospitals - Campus Grosshadern, Munich, Germany, ³Department of Internal Medicine I, Munich University Hospitals - Campus Grosshadern, Munich, Germany, ⁴Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany

Purpose: To investigate and quantify the anti-angiogenic effect of the multikinase inhibitor Sorafenib on experimental prostate carcinomas in rats with DCE-MRI assays of endothelial permeability and tumor vascularity.

Methods and Materials: A total of 16 Copenhagen rats implanted with subcutaneous prostate carcinoma allografts (MLLB-2) were imaged at baseline and after one-week by dynamic MRI at 3T following enhancement with the prototype macromolecular contrast agent albumin-(Gd-DTPA)₃₅. The treatment group (n=8) received daily applications of Sorafenib (10mg/kg bodyweight) via gavage; the control group (n=8) was treated with volume equivalent applications of the solvent of Sorafenib, Cremophor/Ethanol. Quantitative MRI estimates of tumor microvessel permeability (endothelial transfer constant Kₚₛ, ml/100ml/min) and tumor vascularity (blood volume; %) were calculated using the PMI 0.4 software based on a two-compartment kinetic model (1).

Results: Sorafenib significantly suppressed endothelial permeability and blood volume in prostate carcinoma allografts over the treatment course of one week. In Sorafenib-treated tumors (n=8) the transfer constant yielded a significant decrease in endothelial permeability from baseline to day 7 (Kₚₛbaseline=0.62 ± 0.20, Kₚₛday7=0.08 ± 0.09; p<0.01). The blood volume in Sorafenib-treated tumors decreased significantly over the treatment course (BV baseline=5.1 ± 1.0, BV day7=0.56 ± 0.48; p<0.01). No significant alteration of endothelial permeability or tumor vascularity was observed in the control group (n=8).

Conclusion: Sorafenib, a known inhibitor of angiogenesis in renal and liver cancer (2), significantly reduced endothelial permeability and tumor vascularity in a prostate cancer model as assayed by dynamic MRI enhanced with macromolecular contrast media. Pending further investigations, DCE-MRI enhanced with macromolecular contrast media may prove as a valuable tool for monitoring the anti-angiogenic effect of Sorafenib on an individual patient basis.

Figure 1. Depicts the significant (p<0.01) decrease of endothelial permeability in prostate carcinoma allografts following a daily, one-week treatment course of Sorafenib via gavage.

Figure 2. Depicts the significant (p<0.01) decrease of tumor vascularity in prostate carcinoma allografts following a daily, one-week treatment course of Sorafenib via gavage as assayed by dynamic, contrast-enhanced MRI and macromolecular contrast media.

References: